Yuki Gosei Kogyo
Japan Updated 9 July 2026
Yuki Gosei Kogyo is an API manufacturer based in Japan. It holds 5 active US drug master files and 3 valid CEPs across a filed portfolio of 5 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 6 February 2026 as VAI.
2
registered plants
1 with an FDA FEI number
0
filings
across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
7 of 7 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 6 February 2026 VAI US FDA
- 28 July 2021 VAI US FDA
- 17 November 2017 OAI US FDA
- 2 September 2016 VAI US FDA
- 7 March 2014 NAI US FDA
- 22 June 2012 VAI US FDA
- 21 July 2010 OAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Tokyo, Japan | Not on file |
| Japan, Japan | 3002808534 |
What they file, and where
| Molecule | Regulators | Docs |
| Glycine | EDQM, SFDA (Saudi Arabia), US FDA | 3 |
| Isoniazid | EDQM, US FDA | 2 |
| Trifluridine | US FDA | 2 |
| Protamine Sulfate | US FDA | 1 |
| Solifenacin Succinate | EDQM | 1 |
Also appears on these molecule pages
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | None | 1 |
Comparing suppliers?
Choose your molecules and target markets. Yuki Gosei Kogyo comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 6 February 2026.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates